ORIC Pharmaceuticals, a Phase 1 biotech developing small molecule therapies for treatment-resistant cancers, announced terms for its IPO on Monday.
The South San Francisco, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, ORIC Pharmaceuticals would command a fully diluted market value of $424 million.
ORIC Pharmaceuticals was founded in 2014 and plans to list on the Nasdaq under the symbol ORIC. J.P. Morgan, Citi, Jefferies and Guggenheim Securities are the joint bookrunners on the deal. It is expected to price during the week of April 20, 2020.
The article Oncology biotech ORIC Pharmaceuticals sets terms for $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
